Perphenazine - Generic Drug Details

What are the generic sources for perphenazine and what is the scope of freedom to operate?

Perphenazine is the generic ingredient in two branded drugs marketed by Pharm Assoc, Schering, Ani Pharms, Appco, Endo Operations, Macleods Pharms Ltd, Mylan, Rising, Sandoz, Watson Labs Inc, Wilshire Pharms Inc, and Zydus Pharms, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for perphenazine. Sixteen suppliers are listed for this compound.

Summary for perphenazine

US Patents:	0
Tradenames:	2
Applicants:	12
NDAs:	19
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	16
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	27
Patent Applications:	7,118
Drug Prices:	Drug price trends for perphenazine
What excipients (inactive ingredients) are in perphenazine?	perphenazine excipients list
DailyMed Link:	perphenazine at DailyMed

See drug prices for perphenazine

Recent Clinical Trials for perphenazine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Guadalajara	Phase 2
Institute of Experimental and Clinical Therapeutics	Phase 2
Hospital Civil de Guadalajara	Phase 2

See all perphenazine clinical trials

Pharmacology for perphenazine

Drug Class

Phenothiazine

Medical Subject Heading (MeSH) Categories for perphenazine

Antipsychotic Agents

Dopamine Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for perphenazine

N05AB	Phenothiazines with piperazine structure
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for perphenazine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs Inc	PERPHENAZINE	perphenazine	TABLET;ORAL	207582-001	Oct 17, 2016	AB	RX	No	No
Zydus Pharms	PERPHENAZINE	perphenazine	TABLET;ORAL	205232-001	Apr 6, 2020	AB	RX	No	No
Appco	PERPHENAZINE	perphenazine	TABLET;ORAL	210163-003	May 18, 2022	AB	RX	No	No
Zydus Pharms	PERPHENAZINE	perphenazine	TABLET;ORAL	205232-003	Apr 6, 2020	AB	RX	No	No
Sandoz	PERPHENAZINE	perphenazine	TABLET;ORAL	089685-003	Dec 8, 1988	AB	RX	No	No

Perphenazine Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Perphenazine

Introduction to Perphenazine

Perphenazine is a first-generation antipsychotic medication primarily used to treat schizophrenia and severe anxiety disorders. It works by altering the effects of chemicals in the brain, helping to stabilize mood and behavior.

Market Overview

The Perphenazine market has been experiencing steady growth, driven by several key factors:

• Increasing Awareness of Mental Health: Growing awareness of mental health issues and the rising incidence of schizophrenia are significant drivers of the market[3][4].
• Cost-Effectiveness: Perphenazine is less costly than second-generation antipsychotics, with no significant differences in effectiveness, making it a preferred option for many healthcare providers[2].
• Generic Formulations: The development of generic formulations has expanded patient access and contributed to market growth[3].

Market Size and Growth Projections

The global Perphenazine market size was valued at USD 97.8 million in 2021 and is projected to reach USD 135.8 million by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 3.3% during this period[4].

Regional Market Dynamics

The demand for Perphenazine varies across different regions:

• North America: The United States and Canada are seeing a growing demand driven by increasing diagnoses of mental health disorders. Key players like Teva, Sandoz, Endo, and Mylan are strengthening their market presence in this region[3].
• Europe: Countries such as Germany, France, and Italy show potential due to rising healthcare expenditures and government initiatives promoting mental health awareness[3].
• Asia-Pacific: Rapid urbanization in countries like China and India is enhancing the demand for mental health medications. Emerging markets in this region are significant contributors to the market's growth[3].
• Latin America: Brazil and Mexico are witnessing investment opportunities amid growing awareness of mental health issues[3].
• Middle East and Africa: These regions are also emerging markets with significant growth potential due to rising healthcare accessibility[3].

Key Market Players

Several companies are prominent in the Perphenazine market:

• Teva: Known for strategic collaborations and expanding product lines.
• Sandoz: Focused on generic formulations and cost-effective solutions.
• Endo: Differentiates itself through strategic acquisitions and a focus on specialty pharmaceuticals.
• Mylan: Emphasizes affordability and accessibility, contributing to significant revenue streams.
• ZHPHARMA and Shandong Boshan Pharma: These smaller players have gained attention through competitive pricing strategies and targeted marketing efforts in Asia[3].

Emerging Trends

Several trends are shaping the Perphenazine market:

• Increasing Awareness of Mental Health: Driving demand for antipsychotic medications.
• Preference for Generic Medications: Cost-effectiveness is boosting market growth.
• Advances in Drug Formulation: Enhancing efficacy and patient compliance.
• Regulatory Support: Fostering research and development of new therapeutic uses.
• Personalized Medicine: Tailored treatments are gaining popularity.
• Telemedicine: Facilitating easier access to prescriptions[3].

Cost-Effectiveness Analysis

Studies have shown that treatment with Perphenazine is less costly than with second-generation antipsychotics, with no significant differences in measures of effectiveness. This cost-effectiveness is a crucial factor in its market appeal:

• Healthcare Costs: Average total monthly healthcare costs were 20%-30% lower for Perphenazine compared to second-generation antipsychotics[2].
• Quality-Adjusted Life Years (QALYs): No significant differences were observed in QALY ratings between Perphenazine and second-generation medications[2].

Market Challenges and Future Directions

While the market is poised for growth, there are challenges to consider:

• Side Effects: Longer-term neurological and metabolic side effects of Perphenazine require further study[2].
• High Dropout Rates: Clinical trials have been limited by high dropout rates, which can affect the reliability of long-term efficacy data[2].
• Regulatory and Reimbursement Policies: Changes in coverage policies based on comparative effectiveness research (CER) can impact market dynamics. For instance, policies that favor first-generation drugs like Perphenazine can significantly alter market demand and spending[5].

Regulatory Support and Research

Regulatory support for mental health treatment is fostering research and development in the Perphenazine market. Initiatives that promote mental health awareness and the integration of digital health solutions in treatment plans are also driving growth[3].

Conclusion

The Perphenazine market is experiencing moderate growth driven by increasing awareness of mental health issues, the rising incidence of psychiatric disorders, and a greater emphasis on affordable treatment options. Key players are adapting to market demands and regulatory changes, which will continue to influence the competitive dynamics within the Perphenazine segment.

Key Takeaways

• The global Perphenazine market is projected to grow at a CAGR of 3.3% from 2021 to 2031.
• Cost-effectiveness and the development of generic formulations are significant drivers of market growth.
• Increasing awareness of mental health issues and the integration of digital health solutions are key trends.
• Regulatory support and advances in drug formulation are enhancing market dynamics.
• Key players like Teva, Sandoz, Endo, and Mylan are strengthening their market presence through strategic collaborations and expanding product lines.

FAQs

Q: What is the projected market size of Perphenazine by 2031? A: The global Perphenazine market size is projected to reach USD 135.8 million by 2031[4].

Q: What is the CAGR of the Perphenazine market from 2021 to 2031? A: The Perphenazine market is expected to exhibit a CAGR of 3.3% during this period[4].

Q: Which factors are driving the growth of the Perphenazine market? A: Increasing awareness of mental health issues, the rising incidence of psychiatric disorders, and a greater emphasis on affordable treatment options are key drivers[3][4].

Q: How does Perphenazine compare to second-generation antipsychotics in terms of cost and effectiveness? A: Treatment with Perphenazine is less costly than with second-generation antipsychotics, with no significant differences in measures of effectiveness[2].

Q: What are the emerging trends in the Perphenazine market? A: Increasing awareness of mental health, preference for generic medications, advances in drug formulation, regulatory support, personalized medicine, and the rise of telemedicine are key trends[3].

Sources

1. Market Research Intellect: "Perphenazine Drug - Market Research Intellect"
2. PubMed: "Cost-effectiveness of second-generation antipsychotics"
3. Hashnode: "Complete Analysis of the Perphenazine Market's Size, Share and revenue generation"
4. Business Research Insights: "Perphenazine Market Report | Global Forecast To 2031"
5. NBER Working Paper Series: "The Impact of Comparative Effectiveness Research on Health and Spending"